Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Investment Securities (2020 - 2025)

Mirum Pharmaceuticals has reported Gains from Investment Securities over the past 6 years, most recently at $484000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $484000.0 for Q4 2025, down 94.54% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (down 77.61% YoY), and the annual figure for FY2025 was $2.2 million, down 77.61%.
  • Gains from Investment Securities for Q4 2025 was $484000.0 at Mirum Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for MIRM hit a ceiling of $9.2 million in Q2 2024 and a floor of -$8.1 million in Q3 2024.
  • Median Gains from Investment Securities over the past 5 years was $285000.0 (2022), compared with a mean of $833272.5.
  • Peak annual rise in Gains from Investment Securities hit 4488.5% in 2024, while the deepest fall reached 831.43% in 2024.
  • Mirum Pharmaceuticals' Gains from Investment Securities stood at -$1.2 million in 2021, then surged by 123.75% to $285000.0 in 2022, then skyrocketed by 103.86% to $581000.0 in 2023, then surged by 1425.3% to $8.9 million in 2024, then plummeted by 94.54% to $484000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $484000.0 (Q4 2025), $1.3 million (Q2 2025), and $356000.0 (Q1 2025) per Business Quant data.